Publication:
World Bank Pharmaceuticals

dc.contributor.author Govindaraj, Ramesh
dc.contributor.author Reich, Michael R.
dc.contributor.author Cohen, Jillian C.
dc.date.accessioned 2013-06-04T19:31:08Z
dc.date.available 2013-06-04T19:31:08Z
dc.date.issued 2000-09
dc.description.abstract Pharmaceuticals have a major impact on health, on government and household spending, and on health systems. Despite the fundamental role of pharmaceuticals, there remains a profound gap between the benefit which pharmaceuticals have to offer and the reality that for millions of people -- particularly poor and disadvantaged people -- medicines are unavailable, unaffordable, unsafe or improperly used. This World Bank Pharmaceuticals Discussion Paper provides a pragmatic analysis of some of the causes for this gap and strategic directions to help close this gap. The strategic directions outlined in this Pharmaceuticals Discussion Paper complement and reinforce the objectives outlined in the WHO Medicines Strategy: 2000-2003 (World Health Organization, Geneva, 2000, WHO/EDM/2000.1). The WHO strategy describes specific objectives, expected outcomes, and progress indicators in the areas of drug policy, access to essential drugs, quality and safety, and rational use of medicines. Both the World Bank and the WHO initiatives rest on a fundamental commitment to work with governments, on governmental organizations, the private sector, professional bodies, and other key actors to help strengthen the pharmaceutical sector and its ability to contribute to improved health outcomes.. The current burden of disease falling on the two billion people living on less than one dollar per day undermines both individual well-being and collective economic development. Much of this burden of disease can be reduced by securing the availability, affordability, and rational use of essential drugs of assured quality. Yet this aim can not be achieved by governments alone, by individual multilateral organizations working alone, or by any other individual organization. It can only be achieved when committed governments and local organizations are supported by clear, consistency, and mutually compatible approaches by agencies such as the World Bank, WHO, UNICEF, others in the UN family, bilateral donors, and the broader development community. This discussion paper provides an important contribution to this process. en
dc.identifier http://documents.worldbank.org/curated/en/2000/09/3928594/world-bank-pharmaceuticals
dc.identifier.uri http://hdl.handle.net/10986/13734
dc.language English
dc.language.iso en_US
dc.publisher World Bank, Washington, DC
dc.relation.ispartofseries HNP discussion paper series;
dc.rights CC BY 3.0 IGO
dc.rights.holder World Bank
dc.rights.uri http://creativecommons.org/licenses/by/3.0/igo/
dc.subject APPRAISAL REPORTS
dc.subject BIDDING
dc.subject CAPACITY BUILDING
dc.subject CASE STUDY
dc.subject CONTRACEPTIVES
dc.subject CORRUPTION
dc.subject COUNTERFEIT DRUGS
dc.subject DECISION MAKING
dc.subject DELIVERY SYSTEMS
dc.subject DEVELOPED COUNTRIES
dc.subject DEVELOPING COUNTRIES
dc.subject DEVELOPING COUNTRY
dc.subject DEVELOPMENT GOALS
dc.subject DEVELOPMENT INDICATORS
dc.subject DEVELOPMENT NETWORK
dc.subject DEVELOPMENT PARTNERS
dc.subject DEVELOPMENT STUDIES
dc.subject DISTRIBUTION SYSTEMS
dc.subject DRUG FINANCING
dc.subject DRUG INDUSTRY
dc.subject DRUG POLICY
dc.subject DRUG SELECTION
dc.subject ECONOMIC GROWTH
dc.subject ECONOMICS
dc.subject ESSENTIAL DRUGS
dc.subject FINANCIAL SUPPORT
dc.subject FORMAL POLICY
dc.subject HEALTH CARE
dc.subject HEALTH CARE PROVISION
dc.subject HEALTH EXPENDITURES
dc.subject HEALTH NEEDS
dc.subject HEALTH OUTCOMES
dc.subject HEALTH POLICY
dc.subject HEALTH SECTOR
dc.subject HEALTH WORKERS
dc.subject HEPATITIS B
dc.subject HOUSEHOLD INCOME
dc.subject HUMAN CAPITAL
dc.subject HUMAN DEVELOPMENT
dc.subject IMPORTED DRUGS
dc.subject IMPROVED HEALTH
dc.subject INCOME COUNTRIES
dc.subject INDIVIDUAL COUNTRIES
dc.subject INSTITUTIONAL ANALYSIS
dc.subject INTERNATIONAL MARKET
dc.subject INTERVENTION
dc.subject LOW-INCOME COUNTRIES
dc.subject MALARIA
dc.subject MANAGEMENT
dc.subject MANAGEMENT CAPACITY
dc.subject MANAGERS
dc.subject MARKET FAILURES
dc.subject MARKET INCENTIVES
dc.subject MEDICAL SUPPLIES
dc.subject MEDICINE
dc.subject MEDICINES
dc.subject MOTIVATION
dc.subject NATIONAL DRUG POLICIES
dc.subject NATIONAL DRUG POLICY
dc.subject NATIONAL ESSENTIAL DRUG LISTS
dc.subject NATIONAL ESSENTIAL DRUGS LISTS
dc.subject NATIONAL POLICIES
dc.subject NDP
dc.subject NON- GOVERNMENTAL ORGANIZATIONS
dc.subject NUTRITION
dc.subject PARTNER INSTITUTIONS
dc.subject PARTNERSHIP
dc.subject PATENTS
dc.subject PATIENTS
dc.subject PHARMACEUTICAL COMPANIES
dc.subject PHARMACEUTICAL FINANCING
dc.subject PHARMACEUTICAL INDUSTRY
dc.subject PHARMACEUTICAL MANUFACTURERS
dc.subject PHARMACEUTICAL MARKETING
dc.subject PHARMACEUTICAL MARKETS
dc.subject PHARMACEUTICAL POLICIES
dc.subject PHARMACEUTICAL POLICY
dc.subject PHARMACEUTICAL PRICING
dc.subject PHARMACEUTICAL PROCUREMENT
dc.subject PHARMACEUTICAL PRODUCTION
dc.subject PHARMACEUTICAL PRODUCTS
dc.subject PHARMACEUTICAL REFORM
dc.subject PHARMACEUTICAL REGULATORY AGENCIES
dc.subject PHARMACEUTICAL SECTOR
dc.subject PHARMACEUTICAL SUPPLY
dc.subject PHARMACEUTICAL SYSTEMS
dc.subject PHARMACEUTICAL WAREHOUSING
dc.subject PHARMACEUTICALS
dc.subject PHARMACIES
dc.subject POLICY ANALYSIS
dc.subject POLICY DIALOGUE
dc.subject POLICY DOCUMENT
dc.subject POLICY FRAMEWORK
dc.subject POLICY IMPLICATIONS
dc.subject POLICY PROCESS
dc.subject PRICE COMPARISONS
dc.subject PRIMARY HEALTH CARE
dc.subject PRIVATE SECTOR
dc.subject PRIVATE SECTORS
dc.subject PROJECT IMPLEMENTATION
dc.subject PUBLIC AGENCIES
dc.subject PUBLIC HEALTH
dc.subject PUBLIC POLICIES
dc.subject PUBLIC POLICY
dc.subject PUBLIC SECTOR
dc.subject PURCHASING
dc.subject QUALITY ASSURANCE
dc.subject QUALITY CONTROL
dc.subject RATIONAL USE OF DRUGS
dc.subject SAFETY
dc.subject SCHOOLS
dc.subject SOCIAL MARKETING
dc.subject STRUCTURAL ADJUSTMENT
dc.subject TASK TEAM LEADERS
dc.subject TECHNICAL ASSISTANCE
dc.subject THERAPIES
dc.subject VACCINES
dc.subject WIDESPREAD CORRUPTION
dc.subject WORKERS PHARMACEUTICALS
dc.subject BURDEN OF DISEASE
dc.subject HEALTH CARE SYSTEMS
dc.subject MULTILATERAL ORGANIZATIONS
dc.subject HEALTH CARE
dc.subject HEALTH CARE FINANCE
dc.subject HEALTH CARE FINANCING
dc.subject HEALTH SYSTEMS DEVELOPMENT & REFORM
dc.title World Bank Pharmaceuticals en
dspace.entity.type Publication
okr.doctype Publications & Research :: Working Paper
okr.doctype Publications & Research
okr.docurl http://documents.worldbank.org/curated/en/2000/09/3928594/world-bank-pharmaceuticals
okr.globalpractice Poverty
okr.identifier.externaldocumentum 000265513_20040603124203
okr.identifier.internaldocumentum 3928594
okr.identifier.report 28876
okr.language.supported en
okr.pdfurl http://www-wds.worldbank.org/external/default/WDSContentServer/WDSP/IB/2004/06/03/000265513_20040603124203/Rendered/PDF/288760Govindar1Pharmacuetical1whole.pdf en
okr.topic Health Monitoring and Evaluation
okr.topic Pharmaceuticals and Pharmacoeconomics
okr.topic Health Economics and Finance
okr.topic Pharmaceuticals Industry
okr.topic Poverty Reduction :: Poverty Assessment
okr.unit Health, Nutrition & Popultn Team (HDNHE)
okr.volume 1 of 1
relation.isAuthorOfPublication a1e69d35-3306-5de0-937c-3b0f2a30022c
Files
Original bundle
Now showing 1 - 2 of 2
Thumbnail Image
Name:
English PDF
Size:
633.62 KB
Format:
Adobe Portable Document Format
Description:
No Thumbnail Available
Name:
English Text
Size:
101.53 KB
Format:
Plain Text
Description:
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Plain Text
Description: